Exhibit A

Deposition of Paul Galea
December 9, 2009

IN THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF WEST VIRGINIA
CHARLESTON DIVISION

- - -

IN RE: DIGITEK® PRODUCTS LIABILITY LITIGATION MDL NO. 1968

THIS DOCUMENT RELATES TO
ALL CASES

CONFIDENTIAL -
SUBJECT TO FURTHER CONFIDENTIALITY REVIEW

- - -

Wednesday, December 9, 2009

- - -

Videotaped deposition of PAUL GALEA, held at HARRIS BEACH, PLLC, 100 Wall Street, New York, New York, commencing at approximately 9:50 a.m., before Rosemary Locklear, a Registered Professional Reporter, Certified Realtime Reporter, Certified Court Reporter (NJ) and Notary Public.

GOLKOW TECHNOLOGIES, INC.
877.370.3377 ph | 971.591.5672 Fax
deps@golkow.com

Q. Was that at the request of the company or had you been requesting to transfer to the U.S.?

A. It -- it was a bit of both, I could say.

Q. What was -- as you were informed, what was the reason that the company requested it, that you transfer to Actavis Totowa?

A. The initial reason, I was doing an assessment and helping out in the harmonization of the group's corporate manual, and that was basically the main reason.

Q. All right. Well, let's break that into two parts.

What was the assessment that you believe that you were -- that you came here to work on? Assessment of what?

A. Basically, I came to make an assessment of Actavis Totowa, L.L.C.

Q. Overall assessment of the QA Department?

A. No. In general of the company

from a -- from a GMP perspective.

Q. Would you agree with me that there was some serious GMP issues in October of '07 at Actavis Totowa?

MR. ANDERTON: Objection.

You may answer.

THE WITNESS: How do you define serious?

BY MR. MILLER:

Q. Serious? Well, there could have been some GMP problems that would have been, gosh, this is minor, we either need to fix it or we don't need to fix it, or there are some issues where if we don't fix it, then we might be shut down or someone might get hurt.

MR. ANDERTON: Objection.

BY MR. MILLER:

Q. It's okay to answer.

MR. ANDERTON: You may answer.

THE WITNESS: When I first went there, that was not really the scope of my assessment. My assessment was to look at the company and -- and, basically, have a look at

answer.

MR. MILLER: And why?

MR. ANDERTON: On the basis of self-critical analysis privilege.

MR. MILLER: Okay.

BY MR. MILLER:

Q. Sir, we discussed the revised warning letter, which you had a memory of discussing in the past, but not having reading.

And after we've gone through the ten findings that were on the revised warning letter, do you agree with me that the overall thrust of this letter was issues with the quality control and quality assurance?

MR. ANDERTON: Objection.

You may answer.

THE WITNESS: As written by the investigator, yes, potentially they're all quality issues.

BY MR. MILLER:

Q. And you agree with me that the vast majority of them, nine out of ten, involved GMP, good manufacturing

practices.

MR. ANDERTON: Objection.

You may answer.

THE WITNESS: Again, as written, typically, FDA would cite the GMP citations.

BY MR. MILLER:

Q. And when you had the discussion about this letter, did you have an understanding that there were GMP issues with the quality group as a whole or was it only for particular drugs?

MR. ANDERTON: Objection.

You may answer.

THE WITNESS: The discussion was, if I can recollect, looking at the general systems.

BY MR. MILLER:

Q. At the general systems.

So there -- you -- even when you were doing your assessment, roughly the same time as this letter came out, you were never given any instruction or guidance to look at GMP as it pertained to any particular products that were being made; is that correct?

MR. ANDERTON: Objection.

You may answer.

THE WITNESS: No.

BY MR. MILLER:

Q. And, in fact, the GMP at Actavis Totowa, the procedures of GMP as used by the quality group pertained to all drugs, all products that were manufactured.

MR. ANDERTON: Objection.

You may answer.

THE WITNESS: Procedures are not product specific. Procedures tell you how to perform an operation.

BY MR. MILLER:

Q. They're not product specific, therefore, they apply to all products.

A. Procedures do not necessarily apply to a product.

Q. Okay. Well, my question is, you agree that Actavis had issues with their enforcement or use of GMP in the quality group in 2007.

MR. ANDERTON: Objection.

be an issue. That is true.
BY MR. MILLER:
Q. Potentially, and if the FDA had a finding such as that and put it in a warning letter, more likely than not, it's an issue.
MR. ANDERTON: Objection.
You may answer.
THE WITNESS: Not necessarily. Depending on the company's response.
BY MR. MILLER:
Q. Did GMP issues ultimately result in the shutdown of production of all products in August 2008 at Actavis Totowa?
MR. ANDERTON: Objection.
You may answer.
Actually, wait. I instruct you to answer only with respect to Digitek.
THE WITNESS: With respect to Digitek, yes.
BY MR. MILLER:
Q. I'm going to hand you what I'm going to mark as Exhibit 55.
MR. ANDERTON: Thank you.